Prince R A, Brown B T, Jacknowitz A I
Am J Hosp Pharm. 1977 Dec;34(12):1362-5.
The case of a 69-year-old woman with procainamide-induced agranulocytosis is reported, and literature reports of 14 other such cases are reviewed. The patients was exposed to procainamide, prescribed for atrial fibrillation, for 26 days, with a daily dose of 1.5 to 4 g and a total dose of 57.5 g. She recovered from agranulocytosis after discontinuation of the drug and hospital treatment for 16 days. Among the reported cases of procainamide-induced agranulocytosis, the daily dosage ranged from 750 mg to 4.5 g; the total ingested dose before agranulocytosis was observed ranged from 36.5 to 316.3 g. Patients treated with procainamide should be instructed to report any soreness of the mouth, throat or gums; unexplained fever; or any symptoms of upper respiratory tract infection. If white blood cell counts indicate bone marrow depression, the drug should be withdrawn and appropriate evaluation begun at once.
报告了一例69岁女性因普鲁卡因胺诱发粒细胞缺乏症的病例，并对其他14例此类病例的文献报告进行了综述。该患者因房颤服用普鲁卡因胺26天，日剂量为1.5至4克，总剂量为57.5克。停药并住院治疗16天后，她从粒细胞缺乏症中康复。在报告的普鲁卡因胺诱发粒细胞缺乏症病例中，日剂量范围为750毫克至4.5克；在观察到粒细胞缺乏症之前摄入的总剂量范围为36.5至316.3克。应指导服用普鲁卡因胺的患者报告口腔、喉咙或牙龈的任何疼痛；不明原因的发热；或上呼吸道感染的任何症状。如果白细胞计数表明骨髓抑制，应立即停药并开始进行适当评估。
